Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...

(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila) ...

Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major ...

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...

Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.